Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
VXRT:OTCMKTS
Vaxart Inc
$0.74
+0.17%
(+0.0013) 1D
Apr 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VXRT...
Open
$0.74
High
$0.76
Low
$0.72
Mkt. cap
177.72M
Avg. vol.
458.71K
Volume
333.05K
P/E ratio
10.44
52-wk high
$0.84
52-wk low
$0.26
EPS
$0.07
Beta
1.31
Shares outstanding
241.41M
No. of employees
65
News stories
From sources across the web
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc. Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees65
FoundedMar 2004
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitevaxart.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
20.88M
39.73M
72.41M
104.24M
Cost of goods sold
30.74M
49.74M
75.95M
45.15M
Cost of revenue
30.74M
49.74M
75.95M
45.15M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.07M
4.60M
4.28M
3.67M
Operating expense
5.07M
4.60M
4.28M
3.67M
Total operating expenses
35.81M
54.33M
80.22M
48.82M
Operating income
-14.94M
-14.60M
-7.81M
55.42M
Other non operating income
-1.00K
-1.00K
-7.00K
-35.00K
EBT including unusual items
-15.50M
-14.97M
-8.12M
55.39M
EBT excluding unusual items
-15.50M
-14.97M
-8.12M
55.39M
Income tax expense
95.00K
20.00K
17.00K
344.00K
Effective tax rate
-0.61%
-0.13%
-0.21%
0.62%
Other operating expenses
-
-
-
-
Net income
-15.59M
-14.99M
-8.14M
55.04M
Net profit margin
-74.68%
-37.72%
-11.24%
52.81%
Earnings per share
-0.07
-0.07
-0.04
0.24
Interest and investment income
437.00K
310.00K
302.00K
547.00K
Interest expense
-997.00K
-672.00K
-608.00K
-546.00K
Net interest expenses
-560.00K
-362.00K
-306.00K
1.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.69M
-12.41M
-5.73M
57.48M
Gain or loss from assets sale
-
-
5.00K
33.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer